Age-related Macular Degeneration Market Size Will Attain USD 18.29 BN By 2030

According to Nova one advisor, the global Age-related Macular Degeneration market size was estimated at USD 10.40 billion in 2022 and is projected to hit around USD 18.29 billion by 2030, growing at a CAGR of 6.70% during the forecast period 2022 to 2030.

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7607

Key Takeaways:

• By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy
• By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu
• North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment
• Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7607

Report Scope of the Age-related Macular Degeneration Market

The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.’s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche’s Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company’s biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Regional Insights

North America dominated the market in 2022 with a revenue share of over 51.0%. This dominance can be attributed to the increasing prevalence of AMD. According to the American Academy of Ophthalmology, around 15 million North Americans live with AMD. Europe held the second-largest market share in 2021. This is due to the high prevalence of macular degeneration in Europe, which is estimated to rise by around 20% until 2050.

Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the high geriatric population and disease burden. The favorable government initiatives to support the affordability of costly anti-VEGF products may contribute to the market growth. Lucentis and Eylea were added to the National Reimbursement Drug List (NRDL) in China in 2017 and 2019.

Some of the prominent players in the Age-related Macular Degeneration Market include:

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• Biogen
• Samsung Bioepis

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Age-related Macular Degeneration market

• Product
  • Eylea
  • Lucentis
  • Beovu
  • Others
• Disease Type
  • Dry AMD
  • Wet AMD
• Distribution Channel
  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7607

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/